---
title: "Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296638124.md"
description: "Harrow Inc. (NASDAQ: HROW) reported positive results from a clinical study of IHEEZO, an ophthalmic gel used to reduce discomfort during intravitreal injections. The study showed a 58% reduction in patient discomfort compared to proparacaine, with significant improvements sustained up to 24 hours post-procedure. Analysts at William Blair highlighted the findings' importance for patient compliance and long-term growth, maintaining an Outperform rating despite potential short-term stock volatility."
datetime: "2026-08-21T16:09:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296638124.md)
  - [en](https://longbridge.com/en/news/296638124.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296638124.md)
generator: "portal-rs"
---

# Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half

Ophthalmic disease management company **Harrow Inc**. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.

The research evaluated the efficacy of IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3%, an ocular surface anesthetic, during same-day bilateral intravitreal injections (IVT).

According to the company, IHEEZO demonstrated statistically significant advantages at every measured time point.

## Significant Reduction In Discomfort

Patients receiving IHEEZO reported an approximate 58% overall decrease in discomfort compared to their fellow eye treated with proparacaine.

Investigators noted these statistically significant improvements across all four post-procedure assessments.

The medication achieved the most substantial absolute treatment differences right after the injection, which typically represents the period of highest discomfort for the patient.

 **Read Also: Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook** 

## Sustained Patient Relief

At the two-minute mark, absolute treatment differences equaled 1.62 points, with discomfort scores registering at 1.44 for IHEEZO versus 3.06 for the control solution.

One hour post-injection, the absolute difference reached 1.56 points, as patients scored their discomfort at 1.26 with IHEEZO compared to 2.82 for the fellow eye.

This noticeable reduction in pain remained consistent and evident through the final 24-hour evaluation.

## Analyst Sees Attractive Long-Term Growth For Harrow

**William Blair** on Thursday noted that the findings are important, as patient comfort is an important part of IVT injections, and the discomfort associated with current anesthetic and antiseptic protocols has been cited as an important contributing factor to poor compliance.

Analyst **Lachlan Hanbury-Brown** on Thursday wrote that these results also provide further evidence supporting a potential positive outcome from the ongoing Phase IV QUELL study expected to read out later this year, while also supporting continued adoption by retina specialists.

Harrow is advancing its position as a leader in the U.S. ophthalmic pharmaceutical market with the growth of its FDA-approved franchise. William Blair maintains the Outperform rating for the stock.

“We think the seasonality in the company’s underlying business could drive some volatility in the stock, but we believe the long-term growth outlook is attractive,” Hanbury-Brown wrote in an investor note on Thursday.

## Harrow Price Action

**HROW Stock Price Activity**: Harrow shares were down 1.33% at $41.50 at the time of publication on Friday, according to Benzinga Pro data.

*Image via Shutterstock*

 **Read Also: Kratos Stock Gains as International GAIA Orders Put Orbit’s Satellite Push in Focus**

### Related Stocks

- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)
- [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md)
- [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md)
- [VTRS.US](https://longbridge.com/en/quote/VTRS.US.md)
- [KTOS.US](https://longbridge.com/en/quote/KTOS.US.md)

## Related News & Research

- [Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections](https://longbridge.com/en/news/296478792.md)
- [Harrow Chief Scientific Officer Amir Shojaei disposes of 11,250 common shares worth $450,000](https://longbridge.com/en/news/296149417.md)
- [The Precision Peptide Company Inc. Announces Development of Needle-Free Tirzepatide Transdermal Patch | PNGAF Stock News](https://longbridge.com/en/news/296345617.md)
- [Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patients](https://longbridge.com/en/news/296573642.md)
- [FibroBiologics says chondrocyte spheroids repair cartilage in animal study within four weeks](https://longbridge.com/en/news/296228810.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**